Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
medmix AG (MEDX.SW)
Zug, CH
Established in 1922 and headquartered in Zug, Switzerland, Medmix AG stands as a global leader in innovating, manufacturing, and distributing high-precision devices and services. These solutions are meticulously engineered for the controlled mixing, application, and injection of liquids across various viscosities, serving diverse healthcare, consumer, and industrial markets worldwide. The company operates through five key divisions: Dental, Drug Delivery, Surgery, Industry, and Beauty. The Dental segment offers essential tools such as mixing tips, dispensers, needles, and accessories, alongside support services for applications including prosthetics, restorative procedures, anesthesiology, and cosmetic dentistry. In its Drug Delivery segment, Medmix develops critical devices for administering medications like fertility drugs, growth hormones, and treatments for specific diabetes conditions, osteoporosis, and rare diseases. The Surgery segment provides specialized mixing and delivery systems utilized for injecting bone cement and applying hemostatic sealants to manage both internal and external wounds during surgical interventions. For industrial clients, the Industry division produces robust dispensers, cartridges, and mixers for two-component adhesives and sealants, indispensable in sectors such as construction, transportation, electronics, infrastructure, and broader manufacturing. Lastly, the Beauty segment supplies micro brushes, mascara applicators, lip gloss, and concealers. Medmix AG markets its comprehensive product range under well-recognized brands, including Mixpac, Transcodent, Cox, MK, Medmix, Haselmeier, and Geka.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.66% | +1.80% | +8.65% | -4.34% | -14.07% | -19.72% | -14.23% | -54.39% | -79.45% | -79.45% | -79.45% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Industrial - Machinery: +7.4%-7.4% Q4'25: -6.7% (vs Q4'23)
-
EPS growth Industrial - Machinery: +15.6%+183.3% ★ Q4'25: +94.2% (vs Q4'23)
-
FCF margin FCF growth · Industrial - Machinery: +38.2%+7.9% Q4'25: +8.4% (vs Q4'23)
-
EBIT margin Industrial - Machinery: +10.0%+6.1% Q4'25: +4.9% (vs Q4'23)
-
ROIC Industrial - Machinery: +6.8%+3.0% Q4'25: +3.7% (vs Q4'23)
-
Share dilution Industrial - Machinery: +0.0%+1.8% Q4'25: -0.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Industrial - Machinery: -0.65×4.92× Q4'25: 2.64× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
457.30M
est: 457.30M (+0.0%)
|
477.10M
est: 469.54M (+1.6%)
|
486.60M
est: 479.70M (+1.4%)
|
483.90M
est: 484.85M (-0.2%)
|
448.00M
est: 453.21M (-1.2%)
|
458.92M
448.95M – 464.26M
+1.3% YoY
|
489.87M
471.73M – 508.20M
+6.7% YoY
|
508.29M
507.71M – 508.88M
+3.8% YoY
|
548.47M
532.22M – 562.14M
+7.9% YoY
|
| EBITDA |
110.60M
est: 76.70M (+44.2%)
|
68.30M
est: 78.75M (-13.3%)
|
68.40M
est: 80.89M (-15.4%)
|
67.60M
est: 81.76M (-17.3%)
|
79.70M
est: 76.43M (+4.3%)
|
77.39M
75.71M – 78.29M
+1.3% YoY
|
82.61M
79.55M – 85.70M
+6.7% YoY
|
85.72M
85.62M – 85.81M
+3.8% YoY
|
92.49M
89.75M – 94.80M
+7.9% YoY
|
| EBIT |
59.70M
est: 23.87M (+150.1%)
|
18.70M
est: 24.51M (-23.7%)
|
13.00M
est: 25.91M (-49.8%)
|
5.70M
est: 26.18M (-78.2%)
|
27.40M
est: 24.48M (+11.9%)
|
24.78M
24.25M – 25.07M
+1.3% YoY
|
26.46M
25.48M – 27.44M
+6.7% YoY
|
27.45M
27.42M – 27.48M
+3.8% YoY
|
29.62M
28.74M – 30.36M
+7.9% YoY
|
| Net Income |
44.00M
est: 54.17M (-18.8%)
|
11.60M
est: 40.13M (-71.1%)
|
300.0K
est: -1.80M (+116.7%)
|
-7.40M
est: 25.45M (-129.1%)
|
6.40M
est: 14.64M (-56.3%)
|
28.61M
24.97M – 32.25M
+95.4% YoY
|
34.90M
23.88M – 45.92M
+22.0% YoY
|
33.66M
25.30M – 42.02M
-3.6% YoY
|
40.30M
38.75M – 41.61M
+19.7% YoY
|
| SGA |
95.60M
est: 104.40M (-8.4%)
|
103.00M
est: 107.19M (-3.9%)
|
119.00M
est: 111.92M (+6.3%)
|
116.40M
est: 113.12M (+2.9%)
|
114.90M
est: 105.74M (+8.7%)
|
107.07M
104.74M – 108.31M
+1.3% YoY
|
114.29M
110.06M – 118.56M
+6.7% YoY
|
118.59M
118.45M – 118.72M
+3.8% YoY
|
127.96M
124.17M – 131.15M
+7.9% YoY
|
| EPS |
1.07
est: 1.33 (-19.5%)
|
0.28
est: 0.98 (-71.5%)
|
0.01
est: -0.04 (+117.1%)
|
-0.18
est: 0.62 (-129.3%)
|
0.16
est: 0.34 (-52.7%)
|
0.67
0.60 – 0.78
+97.9% YoY
|
0.86
0.58 – 1.11
+28.8% YoY
|
0.81
0.61 – 1.01
-5.5% YoY
|
0.97
0.93 – 1.00
+19.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-20 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-19 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap Value ETF DISV | 0.02% | 905.7K | 0.42% |
| 2 | State Street SPDR S&P International Small Cap ETF GWX | 0.02% | 163.2K | 0.40% |
| 3 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.01% | 826.6K | 0.10% |
| 4 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 574.3K | 0.06% |
| 5 | Dimensional - International Small Cap ETF DFIS | 0.01% | 433.1K | 0.39% |
| 6 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 1.04M | 0.06% |
| 7 | Avantis International Small Cap Equity ETF AVDS | 0.01% | 21.9K | 0.30% |
| 8 | Avantis Responsible International Equity ETF AVSD | 0.00% | 14.8K | 0.23% |
| 9 | Avantis International Equity ETF AVDE | 0.00% | 437.4K | 0.23% |
| 10 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 878.9K | 0.03% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rene Willi | Chief Executive Officer | 2M | — |
| Domenico Truncellito | Head of Corporate Communications & Investor Relations | — | male |
| Francisco Faoro | Chief Technology Officer | — | male |
| Jasper Den Ouden | Chief Human Resources & Sustainability Officer | — | male |
| Jennifer Dean | Global Head of Beauty Business Unit | — | female |
| Kara Zweizig | Head of Business Segment Surgery | — | female |
| Roman Thoenig | Global Head Business Segment Industry | — | male |
| Schops Xavier | Chief Legal Officer, Company Secretary & Head of Corporate Affairs | — | male |
| Ayse Sanlioglu | Global Head of Business Unit Dental | — | female |
| Sven Luginbuehl | Group Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MEDX.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
